20 June 2024
20 June 2024
Day One has entered a licensing agreement for MTX-13, now called DAY301, a novel antibody drug conjugate (ADC) targeting protein-tyrosine kinase 7 (PTK7).
Keeping high-qualified, experienced clinical trial staff on board plays a crucial role in bringing new drugs to market. Dana Durkan of KPS Life discusses how to avoid fraudulent staff, navigate work from home dynamics, and keep hold of your most valued employees.
The high-sustained factor VIII replacement therapy was developed in partnership with Sanofi and is expected to pull in more than $2.7bn in 2030.
The FDA's decision was based on results from the two Phase III CARDIGAN studies in 701 patients.
The companies plan to introduce Immuncell-LC for hepatocellular carcinoma.
Golidocitinib's approval is based on the data from the multinational JACKPOT8 Part B study.
The investment will consolidate, renovate and modernise the 350,000ft² facility in the town of Henrietta.
The team has uncovered a mechanism that could aid in leveraging enzyme communication for drug discovery.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
